在莱特醇脱敏化期间的诺塞博效应:一个案例报告
Asimina Koulouridi1, Panayiota Nikiphorou2, Panayiota Gelastou1
1Department of Oncology, German Oncology Center, Limassol, CYP.
Cureus
|August 13, 2025
概括
一名乳腺癌患者在莱特醇脱敏过程中经历了nocebo反应,而不是真正的药物过敏. 该协议的成功完成允许继续使用基本芳酶抑制剂治疗.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- 乳腺癌的治疗通常需要辅助性内分泌疗法,如芳酶抑制剂.
- 患有多种药物过敏反应史的患者可能会面临治疗坚持方面的挑战.
- 芳香酶抑制剂对于治疗激素受体阳性乳腺癌至关重要.
研究的目的:
- 描述一个乳腺癌患者多种药物过敏症的莱特醇脱敏成功的案例.
- 在内分泌治疗期间调查疑似过敏类反应的管理.
主要方法:
- 一名46岁的女性患有乳腺癌,有药物过敏史,接受了为期三天的莱特醇脱敏方案治疗.
- 患者在三天内接受了安慰剂和升级剂量的莱特.
- 对症状进行监测,管理包括症状治疗和患者披露.
主要成果:
- 患者在安慰剂后经历了 pruritic erythema,这表明了nocebo反应.
- 消毒方案完成后,只有轻微的,可控的副作用 (耳鼻,头痛).
- 患者继续每天服用莱特醇 (2.5毫克) 治疗,没有进一步的过敏并发症.
结论:
- 脱敏可能是乳腺癌患者需要使用芳香酶抑制剂的可行策略,尽管有过敏史.
- 诺塞博反应可以模仿过敏反应,并且应考虑在治疗方案期间出现症状的患者.
- 成功的脱敏使得必要的辅助内分泌治疗成为可能,改善了患者的治疗结果.
相关概念视频
Desensitization and Tachyphylaxis
2.2K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
2.2K
Teratogenicity
2.8K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.8K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
259
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
259
GPCR Desensitization
6.5K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
6.5K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
322
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
322
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
443
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
443


